Cellular therapy Grade 3, 4, or 5 CTACAE Partial Remission leukemia Palliation Pathological stage Active surveillance Neoadjuvant treatment Adenocarcinoma Recurrence Minimal residual disease (MRD) Antibody Drug Conjugate (ADCs) Tyrosine kinase inhibitors (TKIs) ECOG performance status Definitive treatment Sarcoma Surgical margin TNM staging system Adjuvant treatment Relapse Checkpoint inhibitor Tumor Clinical stage Complete remission Maintenance chemotherapy Cure Maintenance chemotherapy performance status Chemotherapy Carcinoma Monoclonal antibody Refractory Complementary therapy Cellular therapy Grade 3, 4, or 5 CTACAE Partial Remission leukemia Palliation Pathological stage Active surveillance Neoadjuvant treatment Adenocarcinoma Recurrence Minimal residual disease (MRD) Antibody Drug Conjugate (ADCs) Tyrosine kinase inhibitors (TKIs) ECOG performance status Definitive treatment Sarcoma Surgical margin TNM staging system Adjuvant treatment Relapse Checkpoint inhibitor Tumor Clinical stage Complete remission Maintenance chemotherapy Cure Maintenance chemotherapy performance status Chemotherapy Carcinoma Monoclonal antibody Refractory Complementary therapy
(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.
Cellular therapy
Grade 3, 4, or 5
CTACAE
Partial Remission
leukemia
Palliation
Pathological stage
Active surveillance
Neoadjuvant treatment
Adenocarcinoma
Recurrence
Minimal residual disease (MRD)
Antibody Drug Conjugate (ADCs)
Tyrosine kinase inhibitors (TKIs)
ECOG performance status
Definitive treatment
Sarcoma
Surgical margin
TNM staging system
Adjuvant treatment
Relapse
Checkpoint inhibitor
Tumor
Clinical stage
Complete remission
Maintenance chemotherapy
Cure
Maintenance chemotherapy
performance status
Chemotherapy
Carcinoma
Monoclonal antibody
Refractory
Complementary therapy